• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What Were the 5 Biggest Controversies in the World of Biosimilars in 2019?

Article

The Center for Biosimilars, a sister site of The American Journal of Managed Care® (AJMC®), reports on the most controversial topics in the biosimilars industry in 2019.

With drug costs continuing to spiral and slower uptake in the United States compared to other parts of the world, it is perhaps natural for observers of biosimilars to ask questions, not only about well-known patent issues, but about deeper issues, such as the way biosimilars are developed, the meaning of interchangeability, and perhaps the very structure of the industry itself. Here’s a look at 5 hot topics from 2019.

Related Videos
Dr Arielle Kauvar
Kavita Nair, PhD, FAAN, professor of neurology and clinical pharmacy, University of Colorado Anschutz
Lindsey Valenzuela, PharmD, APh, BCACP – screenshot by AJMC
Andrew Wolf, MD, assistant professor of neurology, University of Colorado Anschutz
Craig See, MD
 Rakendu Rajendran, MBBS, Virtua Health
Dr Arielle Kauvar
Patrick Sullivan, DVM, PhD
Dr Brian Koffman
Douglas Lazzaro, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.